DK2857023T5 - Anvendelse af odiparcil til behandling af mucopolysaccharidosis - Google Patents
Anvendelse af odiparcil til behandling af mucopolysaccharidosis Download PDFInfo
- Publication number
- DK2857023T5 DK2857023T5 DK14187588.0T DK14187588T DK2857023T5 DK 2857023 T5 DK2857023 T5 DK 2857023T5 DK 14187588 T DK14187588 T DK 14187588T DK 2857023 T5 DK2857023 T5 DK 2857023T5
- Authority
- DK
- Denmark
- Prior art keywords
- odiparcil
- treatment
- pharmaceutical composition
- gags
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Odiparcil til anvendelse ved behandlingen afen mucopolysaccharidosis af type III, VI eller VII.
2. Odiparcil til anvendelse ifølge krav 1, som er beregnet til at blive indgivet med en daglig dosis på omkring 100 mg til omkring 5000 mg.
3. Odiparcil til anvendelse ifølge krav 1 eller krav 2, som er bestemt til oral indgivelse.
4. Odiparcil til anvendelse ifølge krav 3, som er beregnet til indgivelse med føden.
5. Odiparcil til anvendelse ifølge ethvert af kravene 1 til 4, ved behandlingen af Maroteaux-Lamy syndromer.
6. Farmaceutisk sammensætning, som indeholder odiparcil og ét eller flere farmaceutisk acceptable excipienser, til anvendelse ved behandlingen af mucopolysaccharidosis af type III, VI eller VII.
7. Farmaceutisk sammensætning til anvendelse ifølge krav 6, som indeholder 100 mg til 1000 mg odiparcil.
8. Farmaceutisk sammensætning til anvendelse ifølge krav 6 eller krav 7, som foreligger i en oral doseringsform, fortrinsvis i en fast formulering.
9. Farmaceutisk sammensætning til anvendelse ifølge krav 8, som er en tablet.
10. Farmaceutisk sammensætning til anvendelse ifølge ethvert af kravene 6 til 9 ved behandlingen af Maroteaux-Lamy syndromer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1359657A FR3011468B1 (fr) | 2013-10-04 | 2013-10-04 | Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose |
Publications (2)
Publication Number | Publication Date |
---|---|
DK2857023T3 DK2857023T3 (da) | 2016-07-25 |
DK2857023T5 true DK2857023T5 (da) | 2016-08-29 |
Family
ID=49876835
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16159903.0T DK3047851T3 (da) | 2013-10-04 | 2014-10-03 | Anvendelse af odiparcil til behandling af mucopolysaccharidosis |
DK14187588.0T DK2857023T5 (da) | 2013-10-04 | 2014-10-03 | Anvendelse af odiparcil til behandling af mucopolysaccharidosis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16159903.0T DK3047851T3 (da) | 2013-10-04 | 2014-10-03 | Anvendelse af odiparcil til behandling af mucopolysaccharidosis |
Country Status (28)
Country | Link |
---|---|
US (1) | US9561246B2 (da) |
EP (2) | EP2857023B1 (da) |
JP (2) | JP6412927B2 (da) |
KR (2) | KR102328103B1 (da) |
CN (2) | CN109999049B (da) |
AU (1) | AU2014330977B2 (da) |
BR (1) | BR112016007306B1 (da) |
CA (1) | CA2925567C (da) |
CY (2) | CY1117740T1 (da) |
DK (2) | DK3047851T3 (da) |
EA (1) | EA029370B1 (da) |
ES (2) | ES2633806T3 (da) |
FR (1) | FR3011468B1 (da) |
HK (1) | HK1209033A1 (da) |
HR (2) | HRP20160811T1 (da) |
HU (2) | HUE036306T2 (da) |
IL (1) | IL244829A0 (da) |
MA (1) | MA38931B1 (da) |
MX (1) | MX362596B (da) |
MY (1) | MY184721A (da) |
PH (1) | PH12016500541A1 (da) |
PL (2) | PL3047851T3 (da) |
PT (2) | PT3047851T (da) |
RS (2) | RS54907B1 (da) |
SI (2) | SI2857023T1 (da) |
TN (1) | TN2016000111A1 (da) |
UA (1) | UA117934C2 (da) |
WO (1) | WO2015049471A1 (da) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9982288B2 (en) * | 2014-04-30 | 2018-05-29 | The Nemours Foundation | Mucopolysaccharidosis IVA/VII screening and treatment method |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69014064T2 (de) * | 1989-09-22 | 1995-05-18 | Fournier Ind & Sante | Benzopyranon-beta-D-thioxyloside, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung. |
US6866844B2 (en) * | 2002-11-07 | 2005-03-15 | Biomarin Pharmaceutical Inc. | Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
GB0400812D0 (en) * | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
EP1799212A2 (en) * | 2004-10-13 | 2007-06-27 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
FR2903698B1 (fr) * | 2006-07-13 | 2009-01-30 | Fournier S A Sa Lab | Nouveaux derives de 5-thioxylopyranose. |
MX2013000324A (es) * | 2010-06-25 | 2013-02-01 | Shire Human Genetic Therapies | Tratamiento del sindrome de sanfilippo tipo b. |
-
2013
- 2013-10-04 FR FR1359657A patent/FR3011468B1/fr active Active
-
2014
- 2014-10-03 ES ES16159903.0T patent/ES2633806T3/es active Active
- 2014-10-03 RS RS20160504A patent/RS54907B1/sr unknown
- 2014-10-03 JP JP2016519831A patent/JP6412927B2/ja active Active
- 2014-10-03 TN TN2016000111A patent/TN2016000111A1/fr unknown
- 2014-10-03 BR BR112016007306-1A patent/BR112016007306B1/pt active IP Right Grant
- 2014-10-03 EP EP14187588.0A patent/EP2857023B1/fr active Active
- 2014-10-03 CN CN201910022697.5A patent/CN109999049B/zh active Active
- 2014-10-03 DK DK16159903.0T patent/DK3047851T3/da active
- 2014-10-03 SI SI201430031A patent/SI2857023T1/sl unknown
- 2014-10-03 KR KR1020167008265A patent/KR102328103B1/ko active IP Right Grant
- 2014-10-03 CA CA2925567A patent/CA2925567C/fr active Active
- 2014-10-03 HU HUE16159903A patent/HUE036306T2/hu unknown
- 2014-10-03 MY MYPI2016701175A patent/MY184721A/en unknown
- 2014-10-03 KR KR1020217030209A patent/KR102345244B1/ko active IP Right Grant
- 2014-10-03 PL PL16159903T patent/PL3047851T3/pl unknown
- 2014-10-03 PT PT161599030T patent/PT3047851T/pt unknown
- 2014-10-03 EP EP16159903.0A patent/EP3047851B1/fr active Active
- 2014-10-03 MX MX2016004333A patent/MX362596B/es active IP Right Grant
- 2014-10-03 RS RS20170844A patent/RS56235B1/sr unknown
- 2014-10-03 AU AU2014330977A patent/AU2014330977B2/en active Active
- 2014-10-03 ES ES14187588.0T patent/ES2578161T3/es active Active
- 2014-10-03 US US14/506,239 patent/US9561246B2/en active Active
- 2014-10-03 EA EA201690709A patent/EA029370B1/ru not_active IP Right Cessation
- 2014-10-03 CN CN201480053707.7A patent/CN105636597B/zh active Active
- 2014-10-03 MA MA38931A patent/MA38931B1/fr unknown
- 2014-10-03 UA UAA201603536A patent/UA117934C2/uk unknown
- 2014-10-03 SI SI201430342T patent/SI3047851T1/sl unknown
- 2014-10-03 PT PT141875880T patent/PT2857023T/pt unknown
- 2014-10-03 PL PL14187588.0T patent/PL2857023T3/pl unknown
- 2014-10-03 HU HUE14187588A patent/HUE027787T2/en unknown
- 2014-10-03 DK DK14187588.0T patent/DK2857023T5/da active
- 2014-10-03 WO PCT/FR2014/052507 patent/WO2015049471A1/fr active Application Filing
-
2015
- 2015-10-02 HK HK15109703.2A patent/HK1209033A1/zh unknown
-
2016
- 2016-03-21 PH PH12016500541A patent/PH12016500541A1/en unknown
- 2016-03-30 IL IL244829A patent/IL244829A0/en active IP Right Grant
- 2016-07-06 CY CY20161100633T patent/CY1117740T1/el unknown
- 2016-07-07 HR HRP20160811TT patent/HRP20160811T1/hr unknown
-
2017
- 2017-08-04 CY CY20171100839T patent/CY1119212T1/el unknown
- 2017-08-30 HR HRP20171305TT patent/HRP20171305T1/hr unknown
-
2018
- 2018-07-31 JP JP2018143573A patent/JP6545334B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lindahl et al. | Structure of heparan sulphate from human brain, with special regard to Alzheimer's disease | |
JP2002542194A (ja) | 治療におけるグルコシルセラミド合成阻害剤と糖脂質分解酵素の組み合わせ | |
KR100847889B1 (ko) | 곤충유래 글라이코자미노글라이칸 및 그 제조방법 | |
Bach et al. | Mucopolysaccharide accumulation in cultured skin fibroblasts derived from patients with mucolipidosis IV. | |
DK2857023T3 (da) | Anvendelse af odiparcil til behandilng af mucopolysaccharidosis | |
US10092540B2 (en) | Method of treatment of a mucopolysaccharidosis | |
CN113116888B (zh) | 依布硒啉的用途 | |
Majima et al. | Effect of proteoglycan on experimental colitis | |
Shim et al. | Pharmacological activities of a new glycosaminoglycan, acharan sulfate isolated from the giant African snail Achatina fulica | |
JP2003535129A (ja) | 糖尿病性腎障害の治療のためにスロデキシドを用いた方法および組成物 | |
Hayashi et al. | Urinary excretion of acid glycosaminoglycans and hydroxyproline in a patient with oculo-cerebro-renal syndrome | |
WO2024014928A1 (ko) | 단백질 전달을 위한 지질 나노입자 | |
Thunberg et al. | Isolation and characterization of heparin from human mastocytoma tissue | |
Matsui et al. | Three distinct molecular species of proteoglycan synthesized by the rat limb bud at the prechondrogenic stage | |
Chen et al. | Effects of benazepril and valsartan on renal function, vascular endothelial function and oxidative stress factors in the treatment of renal hypertension | |
US7935853B2 (en) | Micronized composition of a 2,4-disubstituted phenol derivative | |
Ghosh et al. | Cartilage derived peptacans: novel nutraceuticals with immunomodulatory, anti-inflammatory and anti-arthritic activities. | |
Kralovec et al. | 8 Glucosamine |